Cinnarizine 1-二苯基甲基-4-肉桂酰基哌嗪

CAS 298-57-7 MFCD00056037

化学结构图

298-57-7
SMILES: C(=Cc1ccccc1)CN1CCN(C(c2ccccc2)c2ccccc2)CC1

化学属性

Mol. FormulaC26H28N2
Mol. Weight369
TSCANo
Melting Point117.0 to 121.0 deg-C
Appearance 脑益嗪盐酸盐,C26H28N2·2HCI,[7002-58-6],熔点192℃,在水中溶解度为2mg/100ml。 powder

别名和识别编码

Chemical NamePiperazine, 1-​(diphenylmethyl)​-​4-​(3-​phenyl-​2-​propen-​1-​yl)​-
MDL NumberMFCD00056037
CAS Number298-57-7
Synonym 1-(Diphenylmethyl)-4-(3-phenyl-2-propenyl)piperazine Cinarizina Inkey Cinarizina Ratiopharm Cinarizine Cinazière Cinna Cinnarizin AL Cinnarizin Ratiopharm Cinnarizin Siegfried Cinnarizin-ratiopharm Cinnarizine Cinnarizine L Tartrate Cinnarizine L-Tartrate Cinnarizine L-Tartrate (1:1) Cinnarizine, (E)-Isomer Cinnarizine, Dihydrochloride Cinnipirine Cisaken Dihydrochloride Cinnarizine Dimitronal L-Tartrate, Cinnarizine R 516 R-516 R516 Stugeron Stugeron Forte Von Ct, Cinnarizin cinnarizin von ct {} {} {} {} {} 1-trans-​Cinnamyl-​4-​diphenylmethylpiperazine
PubChem Substance ID1547484
EC Number206-064-8
Merck Number2305
Chemical Name Translation1-二苯基甲基-4-肉桂酰基哌嗪
Beilstein Registry Number0626121
Reaxys-RN626120
InChIInChI=1S/C26H28N2/c1-4-11-23(12-5-1)13-10-18-27-19-21-28(22-20-27)26(24-14-6-2-7-15-24)25-16-8-3-9-17-25/h1-17,26H,18-22H2/b13-10+
信息真实价格透明    资金保障    专业采购外包团队在线服务   
信息真实价格透明    资金保障    专业采购外包团队在线服务   
品牌质保精细包装    现货库存    一流品牌服务   

分类

  • {SNA} Approved Therapeutics/Drug Candidates, Bioactive Small Molecules, CI-CY, Calcium Channel Modulators,
  • {SNA} Analytical Standards,
  • {SNA} Approved Therapeutics/Drug Candidates, Bioactive Small Molecule Alphabetical Index, CI-CZ, Calcium Channel Modulators, Inhibitors and Activators, Ion Channels, Johnson & Johnson, Voltage-gated Ion Channels, 生物活性小分子, 细胞信号转导和神经科学, 细胞生物学
  • {SNA} Approved Therapeutics/Drug
  • {SNA} Approved Therapeutics/Drug Candidates, CI-CY, Calcium Channel Modulators, Inhibitors and Activators, Ion Channels, Johnson & Johnson, Voltage-gated Ion Channels, 生物活性小分子, 细胞信号转导

安全信息

RTECSTL3430000
WGK Germany2
Personal Protective Equipment Eyeshields, Gloves, type N95 (US), type P1 (EN143) respirator filter
Safety Statements
  • S24/25 Avoid contact with skin and eyes 避免皮肤和眼睛接触;
  • S22 Do not breathe dust 不要吸入粉尘;
TYPE OF TEST            : LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE       : Oral
SPECIES OBSERVED        : Rodent - mouse
DOSE/DURATION           : >4500 mg/kg
TOXIC EFFECTS :
   Behavioral - altered sleep time (including change in righting reflex)
   Behavioral - somnolence (general depressed activity)
   Skin and Appendages - hair
REFERENCE :
   KSRNAM Kiso to Rinsho.  Clinical Report.  (Yubunsha Co., Ltd., 1-5, Kanda
   Suda-Cho, Chiyoda-ku, KS Bldg., Tokyo 101, Japan)  V.1-    1960-
   Volume(issue)/page/year: 16,1735,1982

TYPE OF TEST            : LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE       : Subcutaneous
SPECIES OBSERVED        : Mammal - dog
DOSE/DURATION           : >500 mg/kg
TOXIC EFFECTS :
   Details of toxic effects not reported other than lethal dose value
REFERENCE :
   NIIRDN Drugs in Japan (Ethical Drugs).  (Yakugyo Jiho Co., Ltd., Tokyo,
   Japan)  Volume(issue)/page/year: -,515,1990

TYPE OF TEST            : LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE       : Oral
SPECIES OBSERVED        : Rodent - rat
DOSE/DURATION           : >6500 mg/kg
TOXIC EFFECTS :
   Behavioral - altered sleep time (including change in righting reflex)
   Behavioral - somnolence (general depressed activity)
   Skin and Appendages - hair
REFERENCE :
   KSRNAM Kiso to Rinsho.  Clinical Report.

TYPE OF TEST            : TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE       : Oral
SPECIES OBSERVED        : Human - woman
DOSE/DURATION           : 22500 mg/kg/22W-I
TOXIC EFFECTS :
   Nutritional and Gross Metabolic - other changes
REFERENCE :
   APHRER Annals of Pharmacotherpy.  (Harvey Whitney Books Co., POB 42696,
   Cincinnati, OH 45242) V. 26-    1992-  Volume(issue)/page/year: 26,928,1992

TYPE OF TEST            : LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE       : Intraperitoneal
SPECIES OBSERVED        : Mammal - do

TYPE OF TEST            : TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE       : Oral
SPECIES OBSERVED        : Human - man
DOSE                    : 193 mg/kg
SEX/DURATION            : male 13 week(s) pre-mating
TOXIC EFFECTS :
   Reproductive - Paternal Effects - impotence
REFERENCE :
   APHRER Annals of Pharmacotherpy.  (Harvey Whitney Books Co., POB 42696,
   Cincinnati, OH 45242) V. 26-    1992-  Volume(issue)/page/year: 27,370,1993

TYPE OF TEST            : TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE       : Oral
SPECIES OBSERVED        : Rodent - rat
DOSE                    : 3750 mg/kg
SEX/DURATION            : female 30 day(s) pre-mating
TOXIC EFFECTS :
   Reproductive - Maternal Effects - uterus, cervix, vagina
REFERENCE :
   KSRNAM Kiso to Rinsho.  Clinical Report.  (Yubunsha Co., Ltd., 1-5, Kanda
   Suda-Cho, Chiyoda-ku, KS Bldg., Tokyo 101, Japan)  V.1-    1960-
   Volume(issue)/page/year: 16,1748,1982

Storage condition 0-10°C
Hazard statements
  • H302 Harmful if swallowed 吞食有害
  • H315 Causes skin irritation 会刺激皮肤
  • H317 May cause an allergic skin reaction 可能导致皮肤过敏
  • H319 Causes serious eye irritation 严重刺激眼睛
  • H332 Harmful if inhaled 吸入有害
  • H335 May cause respiratory irritation 可能导致呼吸道刺激
  • H360 May damage fertility or the unborn child 可能对生育能力或未出生婴儿造成伤害
  • H400 Verytoxictoaquaticlife 对水生生物毒性非常大。
  • H410 Verytoxictoaquaticlifewithlonglastingeffects 对水生生物毒性非常大并具有长期影响。
  • H413 Maycauselonglastingharmfuleffectstoaquaticlife 可能对水生生物造成长期持续有害影响。
Precautionary statements
  • P201 Obtain special instructions before use. 使用前获取专门指示。
  • P202 Do not handle until all safety precautions have been read and understood. 已阅读并理解所有的安全预防措施之前,切勿操作。
  • P203
  • P261 Avoid breathing dust/fume/gas/mist/vapours/spray. 避免吸入粉尘/烟/气体/烟雾/蒸汽/喷雾。
  • P264 Wash hands thoroughly after handling. 处理后要彻底洗净双手。
  • P264+P265
  • P270 Do not eat, drink or smoke when using this product. 使用本产品时不要吃东西,喝水或吸烟。
  • P271 Use only outdoors or in a well-ventilated area.? 只能在室外或通风良好的地方使用。
  • P272 Contaminated work clothing should not be allowed out of the workplace. 污染的工作服不得带出工作场所。
  • P273 Avoid release to the environment. 避免释放到环境中。
  • P280 Wear protective gloves/protective clothing/eye protection/face protection. 戴防护手套/防护服/眼睛的保护物/面部保护物。
  • P281 Use personal protective equipment as required. 使用所需的个人防护装备。
  • P301+P312
  • P301+P317
  • P302+P352
  • P304+P312
  • P304+P340
  • P305+P351+P338
  • P308+P313
  • P312 Call a POISON CENTER or doctor/physician if you feel unwell. 如果你感觉不适,呼叫解毒中心或医生/医师。
  • P317
  • P318
  • P319
  • P321 Specific treatment (see … on this label). 具体治疗(见本标签上的)。
  • P330 Rinse mouth. 漱口
  • P332+P313
  • P332+P317
  • P333+P313
  • P333+P317
  • P337+P313
  • P337+P317
  • P362 Take off contaminated clothing and wash before reuse. 脱掉污染的衣服,清洗后方可重新使用
  • P362+P364
  • P363 Wash contaminated clothing before reuse. 被污染的衣服洗净后方可重新使用。
  • P391 Collect spillage. Hazardous to the aquatic environment 收集对水环境有危害的泄漏物。
  • P403+P233
  • P405 Store locked up. 上锁保管。
  • P501 Dispose of contents/container to..… 处理内容物/容器.....
GHS Symbol

其他信息

  • 用途一:长效多功能的血管收缩拮抗剂,能扩张血管,改善血循环,预防血管脆化,可用于治疗脑血管疾病,对颈性眩晕等引起的头痛,头晕失眠、记忆力减退,偏瘫,肢体麻木无力,言语不清等症也有疗效。
  • 上游原料:四氢呋喃 --> 碳酸钾 --> 哌嗪 --> 稀盐酸 --> 己酰氯 --> 二苯甲基哌嗪 --> 二苯基溴甲烷 --> 烯丙苯 --> 二苯氯甲烷 --> 肉桂基氯
  • MOL 文件:298-57-7.mol
  • Sigma Aldrich:298-57-7(sigmaaldrich)
  • color:white
  • 方法一:由无水哌嗪与溴代二苯甲烷制取二苯甲基哌嗪,再与苯丙烯氯缩合而得。二苯甲烷在光照下加热,滴加溴素,在130℃保温1h,即得溴代二苯甲烷,C13H11Br,[776-74-9],熔点45℃。将溴代二苯甲烷滴加到哌嗪甲苯液中,于80-90℃搅拌3h,冷却后用水洗涤反应液,再用10%稀盐酸萃取,将酸层碱化析出沉淀,过滤烘干,得二苯甲基哌嗪。将其溶解在95%乙醇中,加入碳酸钠,在65℃左右滴加苯丙烯氯,滴完后,加热回流4h,趁热过滤,滤液放置过液,析出结晶,过滤,得脑益嗪粗品,经精制,得熔点117-119℃的成品。以二苯甲烷计,总收率48.2%。
  • 周围血管扩张药:桂利嗪是一种哌嗪类钙通道阻滞剂,属于周围血管扩张药。又称肉桂嗪、肉桂苯哌嗪、桂益嗪、脑益嗪,为白色或类白色结晶或结晶性粉末,无臭,几无味。几不溶于水,溶于沸乙醇,易溶于氯仿或苯。桂利嗪对血管平滑肌有扩张作用,对各种血管收缩物质如5-羟色胺、肾上腺素、缓激肽、增压素等有拮抗作用,能缓解血管痉挛。其解痉作用比罂粟碱强,镇静作用不明显。本品能使脑血流量显著增加,能显著地改善脑循环及冠脉循环,作用持续时间也较长,且对各种血管活性物质有抑制作用,能缓解血管痉挛,防止血管脆化。在不影响心率和耗氧量的情况下能增加冠脉血流量和心输出量。静注本品可使血压短暂下降,但口服无此作用。另外,本品还有防止血管脆化作用和抗组胺作用。 口服后30分钟内起效,3~7小时后血药浓度达峰值,作用可持续4小时。血药浓度半衰期3~24小时。 临床上桂利嗪主要用于治疗脑血管障碍及周围血管病如脑栓塞、脑血栓形成、脑动脉硬化、高血压所致的脑循环不全、脑出血与蛛网膜下腔出血恢复期、脑外伤后遗症。对脑循环障碍所致的精神神经病变及冠状动脉硬化症等也有效。亦可用于治疗内耳眩晕症及其他迷路紊乱而引起的恶心、呕吐及运动病。 桂利嗪主要不良反应为:偶见嗜睡、皮疹、胃肠道反应,发热感或头晕,静注使可使血压短暂下降;孕妇慎用;颅内出血、急性脑梗死忌用。

系列性分类


相关产品推荐